NCI Trials for September

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – ABTC-1701

Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients

Adult Brain Tumor Consortium

Nakano, Ichiro

(205) 934-1813


Phase I/II – 10096

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)

Yale University Cancer Center LAO

McKay, Rana Ramzi

(858) 822-6185


Phase II – 10144

A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects

National Cancer Institute LAO

Apolo, Andrea Borghese

(301) 480-0536


Phase II – AMC-102

A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Paclitaxel and Carboplatin in HIV-Positive Women with Locally Advanced Cervical Cancer (LACC)

AIDS Malignancy Consortium

Ndlovu, Ntokozo

2634791631 X 2264


Phase II – NRG-GY012

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer

NRG Oncology

Mackay, Helen Jane

(416) 946-2000


Phase III – S1614

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors

SWOG

Hwang, Jessica P.

(713) 745-4516


Phase III – S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

SWOG

Chapin, Brian Francis

(713) 794-5590


Phase Other – AALL18B3-Q

Discovery of the Genetic Basis of ALL in Children with Down Syndrome

Children’s Oncology Group

Rabin, Karen Ruth

(832) 824-4213


Phase Other – AMC-A04

Development of a Health-Related Symptom Index for Spanish-Speaking Persons Diagnosed with and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)

AIDS Malignancy Consortium

Atkinson, Thomas Michael

(646) 888-0089


Phase Other – ECOG-ACRIN-EAQ161CD

Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting

ECOG-ACRIN Cancer Research Group

Trosman, Julia

(224) 619-2900


Phase Other – WF-1801

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Wake Forest NCORP Research Base

Chan, Michael D.

(336) 713-3600

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login